Cfap46, a cilia and flagella-associated protein located in the photoreceptor connecting cilium, plays a pivotal role in various structures such as the central nervous system, retina, tooth, and trachea cartilaginous ring. Implicated in retinitis pigmentosa 86, Cfap46 exhibits a critical involvement in maintaining cellular integrity and function. Its expression in the photoreceptor connecting cilium underlines its significance in sensory processes and cellular motility, suggesting a crucial role in the structural and functional maintenance of these cellular components. The inhibition of Cfap46 involves a multifaceted approach targeting key cellular pathways associated with its expression and function. Histone deacetylase (HDAC) inhibitors modify chromatin structure, indirectly impacting Cfap46 expression by altering the acetylation status of associated histones. Phosphoinositide 3-kinase (PI3K) inhibitors disrupt downstream signaling pathways, potentially influencing Cfap46 by blocking PI3K-dependent cellular processes.
Inhibition of the transforming growth factor-beta (TGF-β) receptor interferes with TGF-β signaling pathways, indirectly modulating Cfap46 expression. Mitogen-activated protein kinase kinase (MEK) inhibitors affect the MAPK pathway, potentially influencing Cfap46 transcription by altering downstream targets within this pathway. Other inhibitors targeting Notch signaling, p38 mitogen-activated protein kinase (MAPK), bromodomain and extraterminal (BET) proteins, and γ-secretase provide additional means to modulate Cfap46 expression indirectly. Understanding the intricate regulatory network involving Cfap46 and its potential inhibitors provides valuable insights into its functional significance and regulatory mechanisms. The diverse array of inhibitors targeting different cellular pathways emphasizes the complexity of Cfap46 regulation and the need for a comprehensive approach to modulate its expression in various cellular contexts. Further exploration of these pathways may unravel additional details about Cfap46 function and pave the way for future research into interventions associated with Cfap46 dysregulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is a histone deacetylase (HDAC) inhibitor that disrupts the deacetylation of histones, leading to altered chromatin structure. In the context of Cfap46, it indirectly inhibits gene expression by modifying the acetylation status of associated histones. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By blocking PI3K activity, it disrupts downstream signaling pathways, potentially affecting Cfap46 expression and function. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a transforming growth factor-beta (TGF-β) receptor inhibitor. It interferes with TGF-β signaling, which may indirectly modulate Cfap46 through altered regulation of related pathways. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a γ-secretase inhibitor targeting the Notch signaling pathway. By blocking Notch activation, it can impact gene expression, potentially affecting Cfap46 levels. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an HDAC inhibitor that alters chromatin structure. Similar to Vorinostat, it indirectly influences Cfap46 expression by modifying histone acetylation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, disrupting PI3K-dependent signaling pathways. Its impact on Cfap46 could occur through the modulation of these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor. By affecting the p38 MAPK pathway, it may indirectly influence Cfap46 expression and function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a bromodomain and extraterminal (BET) protein inhibitor. It modulates chromatin structure by targeting BET proteins, potentially impacting Cfap46 transcription. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 is a TGF-β receptor inhibitor, similar to SB431542. It disrupts TGF-β signaling pathways, potentially influencing Cfap46 expression through downstream effects. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
GSI-IX is a γ-secretase inhibitor targeting Notch signaling. Its influence on gene expression may extend to Cfap46 through the modulation of Notch-dependent transcriptional events. | ||||||